

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



北京市春立正達醫療器械股份有限公司

Beijing Chunlizhengda Medical Instruments Co., Ltd.*

(A joint stock limited company incorporated in the People's Republic of China with limited liabilities)

(Stock Code: 1858)

SUPPLEMENTAL ANNOUNCEMENT TO THE ANNUAL REPORT FOR THE YEAR ENDED 31 DECEMBER 2022

Reference is made to the annual report (the “**2022 Annual Report**”) of Beijing Chunlizhengda Medical Instruments Co., Ltd.* (the “**Company**”, together with its subsidiaries, collectively as the “**Group**”) for the year ended 31 December 2022 published on 27 April 2023. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the 2022 Annual Report.

Pursuant to paragraph 32(4A) of Appendix 16 to the Listing Rules, the Company would like to provide further information in respect of its significant investments with a value of 5% or more of the Group’s total assets as at 31 December 2022 and its financial assets at fair value through profit or loss, which consisted of the Group’s subscription of certain structured deposit products offered by Bank of Beijing and China Construction Bank (the “**Structured Deposit Products**”).

Further to the announcements of the Company dated 26 January 2022, 28 April 2022, 9 June 2022, 29 June 2022, 2 September 2022 and 13 October 2022, the Company subscribed for certain Structured Deposit Products for the year ended 31 December 2022. Details of the Structured Deposit Products are set out below:

Trustee	Type of entrusted wealth management	Amount of entrusted wealth management (RMB0'000)	Commencement date of entrusted wealth management	Expiry date of entrusted wealth management	Capital Source	Money Flow	Annualised Yield	Actual Gains or (losses) (RMB0' 000)	Actual recovery
Bank of Beijing (Note 1)- Fang Zhuang Sub-branch	Structured deposits	12,000.00	27 January 2022	27 May 2022	Idle capital	Banking	1.35% or 3.2%	126.25	Full Redemption
Bank of Beijing-Daxing Sub-branch	Structured deposits	30,000.00	27 January 2022	27 April 2022	Idle capital	Banking	1.35% or 3.2%	236.71	Full Redemption
China Construction Bank (Note 2) Daxing Sub-branch	Structured deposits	25,000.00	27 January 2022	27 April 2022	Idle capital	Banking	1.6% to 3.18%	196.03	Full Redemption

Trustee	Type of entrusted wealth management	Amount of entrusted wealth management (RMB0'000)	Commencement date of entrusted wealth management	Expiry date of entrusted wealth management	Capital Source	Money Flow	Annualised Yield	Actual Gains or (losses) (RMB0'000)	Actual recovery
Bank of Beijing-Fang Zhuang Sub-branch	Structured deposits	12,000.00	5 May 2022	2 September 2022	Idle capital	Banking	1.35% or 3.04%	119.93	Full Redemption
Bank of Beijing-Daxing Sub-branch	Structured deposits	25,000.00	5 May 2022	2 September 2022	Idle capital	Banking	1.35% or 3.04%	249.86	Full Redemption
China Construction Bank Daxing Sub-branch	Structured deposits	25,000.00	5 May 2022	29 June 2022	Idle capital	Banking	1.6% to 2.888%	108.79	Full Redemption
Bank of Beijing-Fang Zhuang Sub-branch	Structured deposits	12,000.00	13 June 2022	12 October 2022	Idle capital	Banking	1.35% or 3.04%	120.93	Full Redemption
China Construction Bank Daxing Sub-branch	Structured deposits	24,800.00	1 July 2022	29 September 2022	Idle capital	Banking	1.60% to 3.15%	192.62	Full Redemption
Bank of Beijing-Fang Zhuang Sub-branch	Structured deposits	7,000.00	7 September 2022	6 January 2023	Idle capital	Banking	1.35% or 3.15%	73.1	Undue, not redeemed at the end of the reporting period
Bank of Beijing-Daxing Sub-branch	Structured deposits	30,000.00	7 September 2022	6 January 2023	Idle capital	Banking	1.35% or 3.15%	313.27	Undue, not redeemed at the end of the reporting period
China Construction Bank Daxing Sub-branch	Structured deposits	24,000.00	17 October 2022	16 January 2023	Idle capital	Banking	1.50% to 3.08%	181.54	Undue, not redeemed at the end of the reporting period
Bank of Beijing-Fang Zhuang Sub-branch	Structured deposits	3,000.00	17 October 2022	16 January 2023	Idle capital	Banking	1.30% or 3.12%	9.72	Undue, not redeemed at the end of the reporting period
Bank of Beijing-Fang Zhuang Sub-branch	Structured deposits	12,500.00	17 October 2022	16 January 2023	Idle capital	Banking	1.30% or 3.12%	40.51	Undue, not redeemed at the end of the reporting period

Note 1:

Bank of Beijing is a licensed bank in the PRC and a joint stock company established under the laws of the PRC, which provides corporate and personal banking business, treasury business, finance leasing, asset management and other financial services in the PRC. Its shares are listed on the Shanghai Stock Exchange (stock code: 601169). Bank of Beijing (Fangzhuang Branch) and Bank of Beijing (Daxing Branch) are branches of Bank of Beijing. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, Bank of Beijing and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

Note 2:

China Construction Bank is a joint stock commercial bank in the PRC which provides services such as accepting deposits, making loans and offering basic investment products. Headquartered in Beijing, it was listed on the Stock Exchange in October 2005 (stock code: 939) and the Shanghai Stock Exchange in September 2007 (stock code: 601939). China Construction Bank (Daxing branch) is a branch of China Construction Bank. To the best of the Directors' knowledge, information and belief having made all reasonable enquiry, China Construction Bank and its ultimate beneficial owner(s) are third parties independent of the Company and its connected persons.

For the year ended 31 December 2022, the Company recorded an investment income from disposal of the Structured Deposit Products of approximately RMB6,748,000 and a gain on change of fair value of the Structured Deposit Products of approximately RMB9,491,000 in the consolidated income statement. As at 31 December 2022, the Company had a balance of Structured Deposit Products of RMB765,000,000, the fair value of which was approximately RMB767,728,000, representing approximately 23% of the total assets of the Company as at 31 December 2022.

The Company's subscription of the Structured Deposit Products is reasonable and effective use of certain portions of its temporary idle funds from the public issuance of A shares and its internal resources is beneficial for enhancing the overall capital gain of the Group, which is consistent with the core objectives of the Company to safeguard its capital and ensure liquidity.

The above supplementary information does not affect other information contained in the 2022 Annual Report. Save as disclosed in this announcement, the contents of the 2022 Annual Report remains unchanged.

By order of the Board
Beijing Chunlizhengda Medical Instruments Co., Ltd.*
Shi Wenling
Chairman

Beijing, the PRC, 9 August 2023

As at the date of this announcement, the executive directors of the Company are Mr. Shi Chunbao, Ms. Yue Shujun, Ms. Shi Wenling and Mr. Xie Feng Bao; the non-executive director of the Company is Mr. Wang Xin; and the independent non-executive directors of the Company are Ms. Yao Lijie, Mr. Wong Tak Shing and Mr. Weng Jie.

* *For identification purposes only*